GSA Capital Partners LLP Sells 5,529 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

GSA Capital Partners LLP lessened its stake in Inozyme Pharma, Inc. (NASDAQ:INZY) by 13.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,402 shares of the company’s stock after selling 5,529 shares during the quarter. GSA Capital Partners LLP owned approximately 0.06% of Inozyme Pharma worth $185,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of INZY. Deerfield Management Company L.P. Series C purchased a new stake in Inozyme Pharma in the 2nd quarter worth $52,000. Meeder Asset Management Inc. purchased a new stake in shares of Inozyme Pharma in the second quarter worth about $68,000. Values First Advisors Inc. bought a new position in Inozyme Pharma during the second quarter valued at approximately $76,000. SG Americas Securities LLC purchased a new position in Inozyme Pharma during the 3rd quarter valued at approximately $81,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Inozyme Pharma in the 2nd quarter worth approximately $84,000. Institutional investors own 88.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Stifel Nicolaus started coverage on shares of Inozyme Pharma in a report on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price for the company. Jefferies Financial Group restated a “buy” rating and issued a $17.00 target price (up from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a report on Wednesday, November 6th. Wedbush reissued an “outperform” rating and set a $12.00 price objective (down from $15.00) on shares of Inozyme Pharma in a research note on Tuesday, November 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $15.71.

Inozyme Pharma Stock Up 4.5 %

Shares of NASDAQ:INZY opened at $2.81 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. The business has a 50 day simple moving average of $4.66 and a two-hundred day simple moving average of $4.83. Inozyme Pharma, Inc. has a 1 year low of $2.61 and a 1 year high of $7.80. The firm has a market capitalization of $180.51 million, a PE ratio of -1.80 and a beta of 1.54.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. On average, equities analysts predict that Inozyme Pharma, Inc. will post -1.59 EPS for the current year.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.